8-K/A: Rafael Holdings Updates Subscription Rights for Public Warrants in $25 Million Rights Offering

Rafael Holdings provides an update on the subscription rights related to its Public Warrants in connection with its previously announced $25 million rights offering.

Summary

• Rafael Holdings has updated the description of subscription rights for holders of its Public Warrants to purchase Class B Common Stock.
• The update relates to the previously announced rights offering.
• Each holder of a Public Warrant will receive 0.3525 of a non-transferable subscription right.
• Three Public Warrants are required to receive a full subscription right.
• Each full subscription right entitles the holder to purchase 0.603 of a share of Class B Common Stock at $1.28 per share.
• Subscription rights can only be exercised in whole numbers.
• Fractional shares will not be issued.
• The number of shares that may be purchased by each holder of subscription rights will be rounded down to the nearest whole number.
• All other terms of the rights offering remain unchanged.
• Howard Jonas will purchase any unsubscribed shares in a private placement at $1.28 per share.
• The rights offering commenced on May 13, 2025, and expires on May 29, 2025, unless extended or terminated earlier.
• D.F. King & Co., Inc. is the Information Agent for the rights offering.

Sentiment

Score: 7

Explanation: The announcement is fairly neutral, providing an update on the mechanics of the rights offering. The commitment from Howard Jonas to purchase unsubscribed shares is a positive signal. However, the company's disclaimer regarding forward-looking statements and the inherent risks in drug development temper the overall sentiment.

Positives

• The rights offering provides an opportunity for existing warrant holders to increase their stake in the company.
• The standby purchase agreement with Howard Jonas provides assurance that the full $25 million will be raised.
• The funds are intended to support the development and potential launch of Trappsol Cyclo.

Negatives

• The subscription rights are non-transferable, limiting flexibility for warrant holders.
• Fractional shares will not be issued, and the number of shares purchasable will be rounded down, potentially reducing the number of shares a holder can acquire.
• The rights offering is subject to certain conditions and may be terminated by Rafael Holdings.

Risks

• The rights offering is subject to certain conditions and may be terminated by Rafael Holdings prior to its expiration date.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of Trappsol Cyclo is not guaranteed and is subject to clinical and regulatory risks.

Future Outlook

The company intends to use the proceeds from the rights offering to support the development and potential launch of Trappsol Cyclo.

Management Comments

• Howard Jonas, the Company's Executive Chairman and Chairman of the Board will enter into a Standby Purchase Agreement with the Company pursuant to which he will purchase from the Company, in a private placement, any shares of Class B common stock not subscribed for in the proposed rights offering for the same subscription price payable by holders electing to exercise the subscription rights in the proposed rights offering.
• Neither Rafael Holdings nor its Board of Directors has made any recommendation regarding whether Holders should exercise their subscription rights.
• Holders are encouraged to carefully review the subscription materials provided by Rafael Holdings and consult with their legal and financial advisors before making a decision.

Industry Context

Rights offerings are a common method for companies, particularly in the biotech sector, to raise capital to fund research and development activities.

Comparison to Industry Standards

• The terms of the rights offering, such as the subscription price and the number of shares offered per right, are typical for similar offerings in the biotech industry.
• Comparable companies that have used rights offerings include Cyclo Therapeutics, Inc. who initially issued the warrants, and other small-cap pharmaceutical companies seeking to fund clinical trials.

Related Party Transactions

• Howard Jonas, the Executive Chairman and Chairman of the Board, will enter into a Standby Purchase Agreement with the Company to purchase any unsubscribed shares.

Stakeholder Impact

• Shareholders and warrant holders have the opportunity to participate in the rights offering and potentially increase their ownership in the company.
• The funds raised from the rights offering will support the development of Trappsol Cyclo, which could benefit patients with Niemann-Pick Disease Type C1 (NPC1).
• The rights offering could dilute existing shareholders if they do not participate.

Next Steps

• Holders of Public Warrants will need to decide whether to exercise their subscription rights before the expiration date of May 29, 2025.
• Rafael Holdings will proceed with the rights offering and the potential private placement with Howard Jonas.
• The company will continue to develop and evaluate Trappsol Cyclo in clinical trials.

Key Dates

Keywords

rights offering, subscription rights, public warrants, class B common stock, trappsol cyclo, rafael holdings, RFL, RFL-WT